It will be an Australian led multi-institutional phase II trial investigating whether MRI-guided stereotactic radiotherapy improves local control of treated lesions compared with CBCT-guided stereotactic radiotherapy in the treatment of oligometastic cancers in the abdomen. The trial will be performed as a multi-centre Phase 2 randomised trial under the Australasian Gastrointestinal Trials Group (AGITG) and Trans Tasman Radiation Oncology Group (TROG), Australia and New Zealand’s leading radiation oncology trials group.